3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Colitis, Ulcerative
4
Inflammatory Bowel Diseases
3
Crohn Disease
3
Arthritis, Rheumatoid
3
Graft vs Host Disease
2
Cachexia
2
Anorexia
2
Recurrence
1
Rare Diseases
1
Psoriasis
1
Pancreatic Neoplasms
1
Lymphoma
1
Lung Neoplasms
1
Kidney Transplantation
1
Inflammation
1
Hypertension
1
Gastrointestinal Diseases
1
Fatigue
1
Depressive Disorder, Treatment-Resistant
1
Depressive Disorder, Major
1
Depression
1
Carcinoma, Non-Small-Cell Lung
1
Bronchiolitis Obliterans Syndrome
1
Bipolar Disorder
1
Arthritis, Psoriatic
1
Anemia
1
Interventions
ziprasidone
1
Zolpidem
1
Warfarin
1
Vecuronium Bromide
1
Vancomycin
1
Tranexamic Acid
1
Tobramycin
1
Spironolactone
1
Sevelamer
1
Saline Solution
1
Rocuronium
1
Piperacillin, Tazobactam Drug Combination
1
Pentobarbital
1
Oxycodone
1
Nifedipine
1
Nafcillin
1
Molindone
1
Methylprednisolone
1
Lurasidone Hydrochloride
1
Labetalol
1
Infliximab
1
Haloperidol
1
Fosfomycin
1
Clozapine
1
Ciprofloxacin
1
Cidofovir
1
Cefepime
1
Bosentan
1
Aminocaproic Acid
1
Amikacin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Bipolar Disorder
×
Infliximab
×
Clear all
NCT00463580
2025-07-08
Infliximab
Emory University
Phase 4
Completed
60 enrolled
15 charts